ALKS 5461, a novel opioid modulator, produces remission and decreases core depressive symptoms and anhedonia as an adjunctive treatment: A sequential parallel comparison design trial in inadequate responders to antidepressants

Authors
Category Primary study
ConferenceNeuropsychopharmacology
Year 2013
This article has no abstract
Epistemonikos ID: 0ad53be607a895a0c2f5ab67dd412d9493e075a5
First added on: Apr 30, 2026